Alnylam Pharmaceuticals vs Elanco
Elanco reported revenue of $4.7 billion in fiscal 2025, 1.3 times Alnylam Pharmaceuticals' $3.7 billion in fiscal 2025. Alnylam Pharmaceuticals' revenue grew 65.2% in its latest year, and Elanco's grew 6.2%. Free cash flow was $465 million at Alnylam Pharmaceuticals and $284 million at Elanco.
Side by side
| Alnylam Pharmaceuticals | Elanco | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $3.7B | $4.7B |
| Revenue growth | 65.2% | 6.2% |
| Revenue growth a year, last 5 years | 49.8% | 7.6% |
| Gross margin | 81.8% | 55.0% |
| Operating margin | 13.5% | — |
| Net margin | 8.4% | −4.9% |
| Free cash flow | $465M | $284M |
| Free cash flow margin | 12.5% | 6.0% |
| Return on capital | — | −0.1% |
| Net debt to EBITDA | −3.4x | 5.2x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 5.5% | −0.2% |
| Last close | $155.94 | $25.74 |
| P/E at the last close | 66.9× | — |
| Insider trades, last 12 months | sold $40.4 million | bought $2.6 million, sold $100,050 |
| Piotroski F-score | 6 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Alnylam PharmaceuticalsElanco
Operating margin
Percent of revenue
Alnylam PharmaceuticalsElanco
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Alnylam PharmaceuticalsElanco
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Alnylam Pharmaceuticals and Elanco pages.